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ABSTRACT
An unusual case is presented in which ventricular tachycardia at
a rate of 141 beats/min was transiently entrained by rapid
atrial pacing at rates of 150, 155 and 160 beats/min, and was
interrupted by rapid atrial pacing at a rate of 165 beats/min.
During each period of transient entrainment, constant ventric-
ular fusion beats were present except for the last entrained beat,
and progressive ventricular fusion (different fusion QRS com-
plexes) was demonstrated when comparing QRS complex con-
figurations during transient entrainment at each pacing rate.
Interruption of the ventricular tachycardia was associated with
localized conduction block to the right ventricular recording site,
followed by activation of that site from a different direction and
with a shorter conduction time by the subsequent pacing impulse.
These data clearly distinguish transient entrainment of a
tachycardia from overdrive suppression of a tachycardia, and
strongly suggest that reentry was the underlying mechanism of
the ventricular tachycardia.
Originally published in the Journal of the American College of Cardiology,
February 1984.
Review
Beginning with Mayer’s 1906 demonstration of circus
movement of an electrical impulse in a ring of tissue cut
from the bell of the Scyphomedusa (jellyfish) (1), scientists
have pursued the mechanisms responsible for cardiac ar-
rhythmias. Mines (2) and Garrey (3) demonstrated reentry
in large rings of tissue cut from several types of hearts, and
since then almost a century of these studies has led to a
descriptive classification of arrhythmia mechanisms (4) (Ta-
ble 1). Although many of these investigations have been
motivated by pure academic curiosity, the compelling stim-
ulus for most clinician scientists has been the pursuit of the
arrhythmologist’s “golden fleece”: the belief that under-
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INTRODUCTION
In this edition of the Journal, we release the eleventh in a series
of reviews of influential articles that have been previously
published in ACC journals, including the American Journal of
Cardiology (from 1958 to 1982) and JACC (from 1983 to the
present). The publication of these articles is only one aspect of the
ACC’s 50th anniversary commemoration, which highlights 50
years of leadership in cardiovascular care and education. The
articles are intended to encourage reflection on the remarkable
progress made in cardiovascular medicine over time, as well as to
acknowledge the amazing prescience of some early investigators in
anticipating and, in many cases, later guiding developments in
their field.
The working group responsible for selecting these articles and
asking reviewers to write editorials solicited suggestions from
the ACC’s clinical committees and individual members.
The group achieved consensus fairly easily, including whom the
group should ask to prepare the accompanying editorials. We
initially drew up a list of 14 general areas to cover in this series,
but later found that there are several major areas of modern
cardiology, prominently molecular cardiology, in which the truly
landmark articles have, alas, not yet been published in JACC.
Therefore, the working group decided not to categorize by subject,
but instead, to concentrate on the most important articles.
The working group, a task force of the Subcommittee for the
Commemoration of the ACC 50th Anniversary, owes a great
deal to Ms. May A. Roustom and the efficient and tireless staff
at Heart House for facilitating this project. We also wish to
thank all who suggested articles and, most important, the
authors who prepared reviews for their willingness to contribute
their time and wisdom.
Influential Articles in JACC Working Group
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standing the electrophysiologic process(es) responsible for
the initiation and maintenance of cardiac arrhythmias will
lead to specific new ways of preventing arrhythmias and, less
preferable but equally important, terminating them when
they did occur. How have we done?
Arrhythmia termination. The termination part has been
relatively easy. Beginning with the pioneering studies of
Zoll (5), Lown (6), Schuder (7) and others over 30 years
ago, direct current transthoracic cardioversion has provided
a safe and effective means for tachycardia termination. The
implantation of a device, literally and figuratively, began
with Mirowski’s ventricular defibrillator 20 years ago (8),
and within four years had expanded to incorporate the
capability for synchronous ventricular cardioversion (9). An
implantable device to automatically detect an arrhythmia
and cardiovert/defibrillate the heart, radical at the time, has
become the initial treatment of choice for patients with
life-threatening ventricular tachyarrhythmias by consistently
outperforming the best drugs available for these patients
(10). The implantable defibrillator concept most recently
has broadened to encompass an atrial defibrillator (11). One
of the reasons for the success of this form of therapy is that
it is “generic” in the sense that the electric shock will be
successful almost regardless of the arrhythmia mechanism or
electrophysiologic milieu, a very different story from that of
antiarrhythmic drugs (see later discussion).
Arrhythmia prevention. What about arrhythmia preven-
tion? Drugs represent our mainstay for tachycardia preven-
tion, but with their side effects or lack of efficacy, we have
achieved, at best, a mediocre performance (12,13). Why? If
we can understand the mechanism responsible for an
arrhythmia, why can’t we develop a drug that will interrupt
that mechanism and prevent the arrhythmia, much as we
target a specific antibiotic for a specific infectious organism?
It simply isn’t that straightforward, mostly because of the
complexity of the ionic mechanisms that regulate cardiac
electrophysiology. In addition, the unpredictable influence
of exogenous factors such as ischemia, autonomic discharge
or electrolyte changes compounds the interpatient and
intrapatient variability. Furthermore, a channel–channel
interaction can occur in such a way that changes in the
function of one ion channel can have a domino effect on the
function of succeeding ion channels. Confronted by the
reality of such heterogeneity, one can begin to realize the
almost impossible task faced by a drug that has only a single
specific mechanism of action, such as the blocking of one
ion channel. Differences in refractoriness or conduction
velocity of several milliseconds can permit or prevent an
arrhythmia from starting or perpetuating, and drugs that
have only one function cannot be expected to exert high
efficacy, owing to electrophysiologic variability. This may be
why amiodarone, possessing electrophysiologic activity in all
four drug classification categories, appears to be the leader in
arrhythmia prevention (14).
Radiofrequency catheter ablation. Such mixed drug per-
formance has birthed a plethora of many nonpharmacologic
approaches for preventing arrhythmias, including the one
exception to an otherwise ho-hum prevention result—
radiofrequency catheter ablation (15). This technique,
founded on the understanding of arrhythmia mechanisms
and locations, has revolutionized the treatment of patients
with cardiac arrhythmias and has set the “ablationist” apart
as the only cardiology specialist who actually cures a patient
of his disease! We now can eliminate, in a single procedure,
atrial flutter, atrial tachycardias, atrioventricular (AV) node
reentry, AV reentry and other Wolff-Parkinson-White
(WPW)-related arrhythmias with high success rates and
minimal complications, and we are working on how to
eliminate atrial fibrillation. In fact, focal causes of atrial
fibrillation can be ablated with the same success rates as
those for atrial tachycardias in general. It is a fascinating
observation that these foci are often located in the pulmo-
nary veins (16). In the ventricle, tachycardias in patients
with normal hearts can be successfully ablated with accept-
able reliability, whereas those associated with a cardiomy-
opathy or coronary disease remain a challenge.
Reentry and Waldo’s observation. How did it come about
that we were able to achieve such remarkable success with
radiofrequency catheter ablation in so short a span? The
timing was perfect in that the technique came after more
than a decade of investigations that established mechanisms
and sites responsible for clinical arrhythmias, and here is
where Waldo’s contribution (17), highlighted in this issue
of the Journal of the American College of Cardiology, played a
pivotal role. Since the early work on reentry (1–3), we have
understood the electrophysiologic characteristics of slow
conduction and unidirectional block that create this phe-
nomenon, but demonstrating those features required in-
heart recordings of the actual pathways traveled by the
arrhythmia. This was a next-to-impossible feat at the time
of Waldo’s initial studies and is still very difficult today.
Waldo showed us a new way that this might be done.
Instead of having to record the actual pathways traveled by
the arrhythmia, he demonstrated that if one could entrain
the tachycardia—that is, increase the rate of the tachycardia
to a faster rate by pacing, with resumption of the intrinsic
rate of the tachycardia when pacing was stopped—the
Table 1. Mechanism of Arrhythmogenesis
Disorders of impulse formation
Enhanced normal automaticity
Abnormal automaticity
Triggered activity
Early afterdepolarizations
Delayed afterdepolarizations
Disorders of impulse conduction
Block
Unidirectional block and reentry
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presence of reentry could be established (Fig. 1). By deduc-
tive reasoning, he formulated a list of “rules” (Table 2) that
a reentrant tachycardia would have to follow during such a
pacing maneuver that would effectively set it apart from
other mechanisms potentially responsible for the arrhyth-
mia. He showed us that entrainment represented capture or
continuous resetting of the reentrant circuit of the tachy-
cardia by pacing-induced activation. Each pacing stimulus
created a wave front that traveled in an anterograde direc-
tion (orthodromic) and reset the tachycardia to the pacing
rate. A wave front propagating in a retrograde direction
(antidromic) collided with the orthodromic wave front of
the previous beat (Fig. 2). These wave front interactions
created electrocardiographic and electrophysiologic features
that could be recorded easily and that could be explained
only by reentry. This landmark advance enabled us, for the
first time, to prove the reentrant nature of the mechanism of
a clinical tachycardia by using catheter-based procedures,
and it set the stage for applying these principles to help
localize the pathways traveled by the tachycardia wave front
(18). Such localization became essential in our use of
ablation therapy to eradicate complex tachycardias. Thus,
presently, an electrophysiologist is able to pace the heart
during a tachycardia, establish whether reentry is present,
determine whether the pacing site being used is near or
within the reentrant circuit (or perhaps in a “blind loop” area
not at all involved with the reentry) and deliver an ablating
coup de grace. All of this followed from Waldo’s seminal
observation.
The next battlefront: sudden cardiac death. The arrhyth-
mia story is certainly not finished. Sudden cardiac death
remains a major health issue, accounting for 300,000 to
400,000 deaths annually in the U.S. (19). Important gaps in
our knowledge hinder the effective reduction of this mor-
tality (20). Known risk factors are nonspecific, nonsensitive
and nonmechanistic (i.e., they do not provide an under-
standing of the mechanism causing the sudden cardiac
Figure 1. Illustrated criteria for entrainment exemplified in a case
of postinfarct ventricular tachycardia (VT). Left part of panel A,
Two electrocardiographic (ECG) leads of a VT and intracardiac
recordings from a mapping catheter (Map) at a left ventricular site
critical for VT continuation, as well as from the right ventricular
apex (RV). Note diastolic potential (thick arrow) during VT.
Recordings are similarly arranged in all subsequent panels. Right
part of panel A, Right ventricular pacing in the setting of sinus
rhythm. Panel B, Right ventricular pacing at a cycle length (CL)
slightly shorter than VT; this produces a QRS complex that is a
blend between full VT and fully paced (“fusion”). All recordings
are accelerated to the paced CL, and after pacing ceases, the same
VT resumes. Each fused QRS complex is identical and the last
beat is entrained, but surface fusion is absent. Panels C and D,
The same phenomena but at shorter paced CL; note that the fused
QRS complex appears more similar to pacing than it does to VT
as the pacing CL shortens. Panels B–D, Progressive degree of
ECG fusion. The Map recording of panels B–D also shows a
progression of fusion, with both the morphology and timing of a
portion of the electrogram changing with faster pacing. Finally, a
still shorter paced CL results in a sudden change in both the Map
electrogram (block in the small diastolic potential, white arrow)
and the surface ECG, which is now fully paced. When pacing
ceases, VT has been interrupted.
Table 2. Criteria to Establish the Presence of Transient
Entrainment
1. The demonstration of constant fusion beats in the
electrocardiogram (ECG) during the period of rapid pacing
at a constant rate, except for the last captured beat, which is
entrained but not fused (i.e., the last entrained beat
demonstrates the ECG morphology of the spontaneous
tachycardia).
2. The demonstration of progressive fusion (i.e., constant fusion
beats in the ECG during rapid pacing at any constant rate,
but different degrees of constant fusion at different rapid
rates).
3. The demonstration that interruption of the tachycardia is
associated with localized conduction block to a site(s) for one
beat, followed by subsequent activation of that site(s) from a
different direction, as manifested by a change in morphology
of the electrogram at the blocked site(s), and with a shorter
conduction time.
4. The demonstration of a change in conduction time and
electrogram morphology at one recording site when pacing
from another site at two different constant pacing rates, each
of which is faster than the spontaneous rate of the
tachycardia but fails to interrupt it (electrogram equivalent of
progressive fusion).
Reproduced with permission from Waldo AL. Atrial flutter: entrainment character-
istics. J Cardiovasc Electrophysiol 1997;8:337–52.
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death). We frequently use anatomic end points, such as the
presence of reduced ventricular function or the presence of
coronary artery disease as the risk factor, because we do not
have useful electrophysiologic end points. Furthermore,
when we do use an electrophysiologic end point, such as
heart rate variability (21), baroreflex sensitivity (22) or the
presence of premature ventricular complexes (23), these risk
factors fail to offer clues about the initiation and mainte-
nance of the ventricular arrhythmia, thus precluding inter-
ventions based on their presence. T-wave dispersion (24),
although important mechanistically, cannot be measured
accurately from a scalar electrocardiogram at a paper speed
of 25 mm/s, and it probably needs to be assessed with the
accuracy and completeness afforded by techniques such as
body surface mapping. To search for late potentials, the
signal-averaged electrocardiogram (25) should be helpful
mechanistically, but it is too insensitive to be useful. The
relatively new test—T-wave alternans (26)—may be helpful
in the future. Even when the spontaneous onset of ventric-
ular tachycardia/fibrillation is recorded, distinguishing fea-
tures of mechanistic causality are usually absent (27). More
importantly, modification of some risk factors, when used as
a surrogate for sudden cardiac death, can actually worsen the
clinical outcome, as was found in the Cardiac Arrhythmia
Suppression Trial (CAST) (28). These facts make it difficult
to screen large groups and identify persons at risk before an
arrhythmic event occurs, in a cost-effective manner and with
a degree of sensitivity, specificity and predictive accuracy
that justifies a major therapeutic intervention (such as
implanting a cardioverter defibrillator prophylactically) (29).
Substrate risk factor interaction. Although we understand
the basis for many arrhythmic mechanisms, as noted earlier,
we do not understand very well the interactions between the
anatomic/functional cardiac substrate of a patient and the
transient risk factors that finally precipitate sudden cardiac
death in a particular individual (Fig. 3). For example, in
WPW syndrome, the circuit for reentry is always present,
yet tachycardia occurs in paroxysmal episodes. We under-
stand the anatomy and electrophysiology of the WPW
reentry circuit (i.e., we have studied the substrate), but the
transient modulators that trigger the AV reentrant tachy-
cardia are not well understood. Why did tachycardia start at
10:00 AM this morning and not at 10:00 AM yesterday
morning? The same can be stated regarding our understand-
ing of patients with ventricular tachycardia pathways laid
down by a myocardial infarction. Furthermore, our testing
paradigms are limited because initiation of arrhythmias in
most, but not all (30), animal models does not occur
spontaneously (recent knockout mice models may prove
useful). It is investigator-controlled, using methods such as
coronary occlusion/release, prolonged rapid pacing, drug
administration and autonomic manipulation. Some of these
experimental manipulations do not accurately replicate the
clinical onset of arrhythmias in patients with coronary
disease and dilated cardiomyopathy, the two largest groups
of patients with sudden cardiac death. These factors, plus
the varied routes leading to the final common pathway of
ventricular tachycardia/fibrillation or a bradyarrhythmia,
make testing interventions difficult and hinder the arrhyth-
mologist’s quest to match a precise arrhythmia mechanism
Figure 2. Diagram of the reentrant circuit during spontaneous atrial flutter and during transient entrainment of the atrial flutter. The left
diagram shows the reentrant circuit during spontaneous type I atrial flutter (AFL). The “f ” represents the circulating wave front of the
atrial flutter. The middle diagram shows the introduction of the first pacing impulse (x) during rapid pacing from a high atrial site during
the atrial flutter. The large arrow indicates the entry of the pacing impulse into the reentrant circuit, whereupon it is conducted
orthodromically (Ortho) and antidromically (Anti). the antidromic wave front of the pacing impulse (x) collides with the previous beat,
in this case the circulating wave front of the spontaneous atrial flutter (f), resulting in an atrial fusion beat. This, in effect, terminates the
atrial flutter. However, the orthodromic wave front from the pacing impulse (x) continues the tachycardia, resetting it to the pacing rate.
The right diagram shows the introduction of the next pacing impulse (x 1 1) during rapid pacing from the same high atrial site. The large
arrow again indicates the entry of the pacing impulse into the reentrant circuit, whereupon it is conducted orthodromically and
antidromically. Once again, the antidromic wave front from the pacing impulse (x 1 1) collides with the orthodromic wave front of the
previous beat. In this case, it is the orthodromic wave front of the previous paced beat (x), resulting in an atrial fusion beat. The
orthodromic wave front from the pacing impulse (x 1 1) continues the tachycardia, resetting it to the pacing rate. The arrows indicate
the direction of spread of the impulses; the serpentine line indicates slow conduction through a presumed area of slow conduction
(stippled region) in the reentrant circuit; and the black dots with tails indicate bipolar electrodes at the high atrial pacing site, the
posteroinferior portion of the left atrium (PLA) and another atrial site. (Reproduced with permission from Waldo AL. Atrial flutter:
entrainment characteristics. J Cardiovasc Electrophysiol 1997;8:337–52.)
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with a specific therapeutic intervention. We may be close to
achieving this goal in some disease states, such as the long
QT syndrome (31), but the latter is uncommon and
represents the exception rather that the rule. Although we
do have acceptable therapy to terminate the ventricular
arrhythmia after its onset (i.e., the implantable cardioverter
defibrillator), the biggest challenges are to identify the
at-risk patient before the event occurs and then to prevent
the ventricular arrhythmia from occurring at all. These two
steps, identification and prevention, are very difficult to
achieve given the present state-of-the-art, but in addition to
prevention of the primary disease state, which is a very
long-term goal, they are the most important long-term
goals that we have.
Investigative approach to sudden cardiac death. In the
investigation of arrhythmic mechanisms, studies on single
cells and cellular elements are vital. These kinds of studies
eliminate many of the ambiguities found in more complex
in vitro preparations and intact organs, but the ambiguities
themselves may be important factors in the development of
some arrhythmias. Therefore, the powerful specificity af-
forded by in vitro techniques must be integrated with less
controllable but perhaps more clinically relevant in vivo
studies. Indeed, some questions—for example, the role of
transient risk factors—can be answered only by using in vivo
animal models that faithfully replicate human conditions or,
more probably, by studying patients themselves. Of the
three major research pathways (basic, translational and
clinical), the clinical utility of basic science inherently is
associated with a high degree of clinical uncertainty. To
reduce this level of uncertainty, some basic science needs to
be focused on clinically relevant problems in order to
provide a research structure that allows the rapid translation
of the basic science advances to the clinic. Such an orien-
tation requires close communication among individuals in
all three disciplines, which can be achieved only by a
propinquity that breeds interaction; all investigators must
“share the same coffee pot” to promote discussion and the
kind of relationship that results in clinical advances. Spe-
cialized Centers of Research grants are ideal in this regard
because they can be molded around a clinical project that
interweaves basic and translational research about a core of
clinical issues. The animal projects can be designed to
interact with, expand and supplement the objectives and
hypotheses put forth in the clinical research. Thus, the
research concepts emanate from the clinical problems and
intersect with the animal studies at various levels, from
molecular to in vitro to in vivo investigations. Clinician–
scientists are needed to make this happen (32).
The exploration of mechanisms responsible for sudden
cardiac death must be divided into three parts. These
include a search for the trigger precipitating the lethal
cardiac arrhythmia, a study of the underlying substrate on
which the trigger acts and an investigation of the interac-
tion(s) between the two that caused the event that generated
the arrhythmia (Fig. 3). Substrates are much easier to
control and characterize, and they therefore represent the
bulk of most research efforts to date. Triggers are very
difficult to evaluate because they are evanescent and variable,
and there are few models apart from humans of truly
Figure 3. Venn diagram showing overlap between substrate characteristics, transient initiating events and intrinsic arrhythmia mechanisms
to produce electromechanical dissociation (EMD) asystole, ventricular tachycardia (VT) or ventricular fibrillation (VF). (Reproduced with
permission from Zipes and Wellens [19].)
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spontaneous sudden cardiac death. One of the generally
accepted triggers is the autonomic nervous system through
its influence on cardiac excitable properties (33). Because
triggers must act on a receptive substrate to create an arrhyth-
mia, one needs to also investigate myocardial structure–
function patterns, particularly when modulated by the
autonomic nervous system. In addition, we now know that
the heart can undergo progressive changes in structure and
function owing to a variety of stimuli, such as rate (34–37),
ischemia (38), stretch (39), genetic predisposition (40) and
others. Remodeling, as this process is often called, probably
plays a crucial role in the pathogenesis of many arrhythmias,
particularly by influencing and potentially altering the elec-
trophysiologic and anatomic milieu and interactions with
triggers. Remodeling has different causes, depending on the
initiating event and its duration. Remodeling can range
from short-term alterations of ion concentration and chan-
nel function, perhaps proceeding from metabolic influences,
to longer-term changes resulting from altered gene expres-
sion in regulating protein synthesis and assembly, to very
long-term structural revisions from damage caused by fibro-
sis, fatty infiltration and similar processes (41). A better
understanding of these changes will provide more insight
into the arrhythmia mechanisms that precipitate sudden
cardiac death and will aid in designing unique antiarrhyth-
mic approaches to prevent this calamity.
Sudden cardiac death: what to do now? It is clear that the
search for solutions to the problem of sudden cardiac death
is challenging. Given the sustained effort that will be
required to develop methods to accurately identify persons
at risk, as well as ways to prevent sudden cardiac death, a
short-term plan is necessary, founded on delivering cardio-
pulmonary resuscitation and defibrillation to the victim as
soon as possible (42). In 1992, it was suggested that
cardiopulmonary resuscitation training be given as a man-
datory course in high school to increase the pool of
bystanders who might be able to help when a person has a
cardiac arrest (43). It was also suggested that external
defibrillators “be as accessible as fire extinguishers” (43). We
must use such an approach now to be able to rapidly
resuscitate the victim of sudden cardiac death, while we also
continue to pursue our golden fleece.
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